Association between clinicopathologic parameters and ERG translocation in prostate cancer
Other Titles
전립선 암에서 임상병리학적 결과와 ERG 유전자전위의 연관성
Authors
이승렬
Degree
박사
Issue Date
2018
Description
의학대학원/박사
Abstract
Introduction: We evaluated associations between pathologic factors and erythroblast transformation-specific (ETS)-related gene (ERG) fusion with TMPRSS2 (transmembrane protease serine 2 gene) in prostate cancer patients. Using next-generation sequencing, we identified target genes and regulatory networks. Methods: ERG expression in 60 radical prostatectomies performed at Severance Hospital, Yonsei University College of Medicine in 2015 was compared with pathological findings by association rule mining with the Apriori algorithm. Whole-exome and RNA sequencing were performed on three formalin-fixed, paraffin-embedded ERG-positive and -negative prostate cancer samples. A network diagram identifying dominant altered genes was constructed using Cytoscape open source bioinformatics platform and GeneMania plugin. Results: Pathologic conditions positive for perineural invasion, apical margins, and Gleason scores 6 and 7 were significantly more likely to be ERG-positive than other pathologic conditions (p=0.0009), suggesting an association between ERG positivity, perineural invasion, apical margins and Gleason scores 6 and 7 (Firth’s logistic regression: OR 17.952, 95% CI: 2.391-134.815, p = 0.0050). Results of whole-exome and RNA sequencing identified 97 somatic mutations containing common mutated genes. Regulatory network analysis identified NOTCH1, MEF2C, STAT3, LCK, CACNA2D3, PCSK7, MEF2A, PDZD2, TAB1 and ASGR1 as pivotal genes. NOTCH1 appears to function as a hub because it had the highest node degree and betweenness. NOTCH1 staining was found 8 of 60 specimens (13%), with a significant association between ERG and NOTCH1 positivity (p=0.001). Conclusions: Evaluating the association between ERG fusion and pathologic factors, and identifying the regulatory network and pivotal hub may help to understand the clinical significance of ERG-positive prostate cancer.